Updated COVID-19 Vaccines Offer Significant Protection for Children and Adolescents, CDC Analysis Finds
A new analysis from the Centers for Disease Control and Prevention (CDC) reveals that the 2024-25 COVID-19 vaccine substantially reduces the risk of emergency department (ED) and urgent care (UC) visits among US children and adolescents. Published on Thursday in the Morbidity and Mortality Weekly Report, the findings offer crucial data as federal vaccine recommendations face increasing scrutiny.
The CDC study, based on data from more than 98,000 pediatric cases across nine states, assessed the effectiveness of the updated vaccines – designed to target the Omicron JN.1 and JN.1-derived sublineages – in preventing COVID-related ED and UC visits between August 2024 and September 2025. Researchers utilized electronic health records in a test-negative, case-control study to measure the added protection provided by the 2024-25 dose, even among individuals with existing immunity from prior infection or previous vaccination.
High Vaccine Effectiveness in Young Children
Among children aged 9 months to 4 years, vaccine effectiveness (VE) against COVID-associated ED/UC visits reached 76% during the initial 7 to 179 days post-vaccination. Importantly, this level of protection remained stable for up to 299 days. These results are comparable to, or even exceed, VE estimates observed in adults during the same period and surpass those reported for young children during the 2023-24 season. According to the study authors, the heightened effectiveness in 2024-25 may be linked to evolving infection patterns or a reduction in circulating variant changes.
The analysis also highlighted a concerning trend: during the 2024-25 season, hospitalization rates among US infants aged 6 to 11 months were higher than those of all adult age groups except individuals 65 years and older. This underscores the potential benefits of COVID-19 vaccination for eligible infants, the researchers noted.
Protection for Older Children and Teens
In children and adolescents aged 5 to 17 years, the 2024-25 vaccines reduced the risk of an ED/UC visit by 56% within the first 7 to 179 days after vaccination. While protection decreased slightly to 45% when the observation window extended to 7 to 299 days, the overall impact remained significant.
Study Limitations and Ongoing Debate
The authors acknowledged several limitations within the study. These included the potential for ED and UC visits related to non-COVID illnesses, possible misclassification of vaccination status, incomplete records of prior infections, and challenges in accurately measuring VE against hospitalization due to fewer severe cases in children this season. Despite these caveats, the results strongly suggest that the 2024-25 vaccines offer meaningful additional protection for children and teens, even those with pre-existing immunity.
These findings arrive at a pivotal moment, as longstanding federal vaccine recommendations are being actively reevaluated and, in some instances, rolled back. This year, under the direction of US Health and Human Services Secretary Robert F. Kennedy Jr., a well-known vaccine skeptic, the federal government removed its recommendation for routine COVID vaccination for healthy pregnant women and children. This shift in policy raises questions about the future of public health strategies regarding COVID-19 and the role of vaccination in mitigating its impact on vulnerable populations.
